ReviewImmunity, inflammation and disease2025
The Etiopathogenesis of Kawasaki Disease: Evolving Understanding of Diverse Triggers.
Review in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Benchmarking large language models for cell-free RNA diagnostic biomarker discovery.Nature communications · 2026Article
- Construction and validation of a diagnostic model for Kawasaki disease based on neutrophil-related genes and analysis of immune infiltration.Translational pediatrics · 2026Article
- Identification of programmed cell death and mitochondria correlated biomarkers for Kawasaki disease by integrated bioinformatics and machine-learning algorithms with RT-qPCR verification.Frontiers in genetics · 2026Article
- Kawasaki disease vs. MIS-C in a child with congenital coronary artery anomaly: a case report.Frontiers in pediatrics · 2026Article
- Human pathological findings in Kawasaki disease: a narrative review of autopsy and biopsy evidence.Frontiers in immunology · 2026Review
- The Etiopathogenesis of Kawasaki Disease: Evolving Understanding of Diverse Triggers.Immunity, inflammation and disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundKawasaki disease (KD) is a leading cause of acquired heart disease in children. Evidence suggests that microbial and nonmicrobial triggers for KD differ across geographical regions and environmental conditions. Although the precise triggers remain unidentified, KD is likely caused by microbial or environmental agents acting on genetically predisposed children. RECENT
findingsInsights into KD pathogenesis have also been derived from three well-established murine models, which highlight diverse vasculitis-inducing pathways. The diversity of microbial triggers supports the hypothesis that KD arises from immune-mediated responses rather than direct infection. Pathogen-associated molecular patterns (PAMPs), microbe-associated molecular patterns (MAMPs) and inflammatory cell death-linked damage-associated molecular patterns (DAMPs) play critical roles in KD pathogenesis. Furthermore, genetic polymorphisms associated with KD, such as ITPKC, CASP3, and FCGR2A, contribute to immune activation by promoting inflammasome activation, pyroptosis and antibody-dependent enhancement (ADE), thereby intensifying inflammation. Oxidative and nitrative stress further amplify inflammatory responses, with their interplay potentially driving KD onset. The relatively low recurrence rate of KD, despite its diverse triggers, may partly be explained by the presence of anti-DAMP antibodies. Historically, reduced exposure to infections and improved sanitation may have led to lower levels of anti-DAMP antibodies, potentially contributing to the increased incidence of KD observed over time.
conclusionContinued research into microbial and immune mechanisms is crucial to advance our understanding of KD pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.